1. Foxman B. Urinary Tract Infection Syndromes Occurrence, Recurrence, Bacteriology, Risk Factors, and Disease Burden. Infectious Disease Clinics of North America.2014;28(1):1-13.doi:10.1016/j.idc. 2013.09.003.
2. Foxman B. Epidemiology of urinary tract infections: Incidence, morbidity, and economic costs. Dm Disease-a-Month. 2003;49(2):53-70. doi: 10.1067/mda.2003.7.
3. Khoshnood S, Heidary M, Mirnejad R, et al. Drug-resistant gram-negative uropathogens: A review. Biomedicine & Pharmacotherapy. 2017;94:982-94. doi: 10.1016/j.biopha.2017.08.006.
4. El Bcheraoui C, Mokdad AH, Dwyer-Lindgren L, et al. Trends and Patterns of Differences in Infectious Disease Mortality Among US Counties, 1980-2014. JAMA. 2018;319(12):1248-60. doi: 10.1001/jama.2018.2089.
5. Bader MS, Loeb M, Brooks AA. An update on the management of urinary tract infections in the era of antimicrobial resistance. Postgraduate Medicine. 2017;129(2):242-58. doi: 10.1080/00325481.2017.1246055.
6. Peng YX, Liu XQ, Wen LL, et al. Antibacterial Activities of Five Chinese Medicines of Rhei Radiset Rhizoma and Their Chemical Constituents Against Multidrug-resistant Clinical Bacteria Isolates.Chinese Journal of Experimental Traditional Medicine Formulae. 2014;20 (22):103-107.
7. Li DY, Hou Y, Zhang KY, et al. Reseach progress on mechanism of anti-drug resistance of traditional Chinese medicine.China Medical Engineering. 2017;25(11):16-19.
8. Hou X,Wang LX. Research Progress of Sanjin tablets. Evaluation and Analysis of Drug use in Chinese Hospitals. 2016;16(08):1148-1151.
9. Yi JC.Clinical observation of levofloxacin and Sanjin tablets in the treatment of urinary tract infection.JiangXi Medical Journal. 2015;50 (5) :447-448.
10. Dong XL.Clinical efficacy and safety of Sanjin tablets combined with levofloxacin tablet in the treatment of urinary tract infection. The world's Latest Medical Information Abstracts. 2017;17(30):169-170.
11. Zheng HY, Hu JG. Efficacy of Sanjin tablets combined with gatifloxacin in the treatment of acute simple lower urinary tract infection[J]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine. 2013; 23 (9) :724-726.
12. Meng J, Zou Z, Lu C, et al. Identification and Characterization of Bioactive Compounds Targeting Uropathogenic Escherichia coli from Sanjin Tablets. Journal of Chemistry. 2015 doi: 10.1155/2015/789809.
13. Pu X, Zhang LY, Zhang JH.A systematic Review of Sanjin tablets in the treatment of simple urinary tract infection: a randomized controlled trial. Lishizhen Medicine and Materia Medica Research. 2016;27 (4) :1012-1014.
14. Li WH, Zhu WT, Han L, et al. Pharmacoeconomic Analysis of Two Integrated Traditional and Western Treatment Formulas of Lower Urinary Tract Infection. Chinese Archives of Traditional Chinese Medicine. 2012;30 (2) :303-305.
15. Hawkey PM. Multidrug-resistant Gram-negative bacteria: a product of globalization. Journal of Hospital Infection. 2015;89(4):241-47. doi: 10.1016/j.jhin.2015.01.008.
16. Penchovsky R, Traykovska M. Designing drugs that overcome antibacterial resistance: where do we stand and what should we do? Expert Opinion on Drug Discovery. 2015;10(6):631-50. doi: 10.1517/17460441.2015.1048219.
17. World Med A. World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects. JAMA. 2013;310 (20): 2191-94. doi: 10.1001/jama.2013.281053.
18. SFDA. Good Clinical Practice of Pharmaceutical Products. 2003.
19. Flory J, Emanuel E. Interventions to improve research participants' understanding in infor
-med consent for research - A systematic review. JAMA. 2004;292(13):1593-601. doi: 10.1001/jama.292.13.1593.
20. Jefford M, Moore R. Improvement of informed consent and the quality of consent documents. Lancet Oncology. 2008;9(5):485-93. doi: 10.1016/s1470-2045(08)70128-1.
21. DiNubile MJ. Double-blind active-control trials: Beware the comparator you keep. Clinical Infectious Diseases. 2008;47(8):1064-67. doi: 10.1086/592068.
22. Juni P, Altman DG, Egger M. Systematic reviews in health care-Assessing the quality of controlled clinical trials. British Medical Journal. 2001;323(7303):42-46. doi:10.1136/bmj.323.7303.42.
23. Chan AW, et al. SPIRIT 2013 statement: defining standard protocol items forclinical trials. Ann Intern Med. 2013;158(3):200-7.
24. Antes G. The new CONSORT statement. BMJ. 2010;340:c1432.
25. Liu H, Xie JX, Xu ZS. Clinical Study of Sanjin Pills to Acute Simple Bacterial Lower Urinary Tract Infection Based on the Contrast of Levofloxacin Tablets. Acta Chinese Medicine. 2017;32(12):2489-2492.
26. Na YQ,Sun G,Ye ZQ, et al.Guidelines for the diagnosis and treatment of Urological Diseases in China (2014 ed).Beijing:People’s Medical Pulishing House. 2013.
27. Wu HX.The National Standard Clinic Terminology of Traditional Chinese Medical Diagnosis and Treatment Was Released and Implemented. Chinese Journal of Information on Traditional Chinese Medicine. 1998;(05):25.
28. Tian DL. Internal Medicine of Traditional Chinese Medicine .Beijing:Chinese Medicine Press. 2005.
29. Jiang CB,Song YL,Ren Y, et al.Clinical Observation on the Effect of Jiawei Zishen Tongguan Decoction in Treating Stranguria of Kidney Deficiency and Dampness-Heat Syndrome. Chinese Journal of Integrated Traditional and Western Nephrology. 2015;16(8):712-714.
30. Yan SY, He LY, Liu BY. How to Keep the Blinding of Clinical Trials in Chinese Medicine. Modernization of Traditional Chinese Medicine and Materia Medical. 2014;16(12): 2527-2530.
31. Hu LP, Bao XL, Wang Q. Methods and Analysis of Realizing Randomized Grouping. J Chin Integr Med. 2011; 9(7): 711-714.
32. Dalhoff A, Schubert S, Vente A. Pharmacodynamics of Finafloxacin, Ciprofloxacin, and Le-vofloxacin in Serum and Urine against TEM- and SHV-Type Extended-Spectrum-beta-Lacta
-mase-Producing Enterobacteriaceae Isolates from Patients with Urinary Tract Infections. Antimicrobial Agents and Chemotherapy. 2017;61(5) doi: 10.1128/aac.02446-16.
33. Homma Y, Yoshida M, Seki N, et al: Symptom assessment tool for overactive bladder syndrome--overactive bladder symptom score. Urology. 2006; 68:318-323.
34. Homma Y.Yoshida M.Obara K.et al.Developmentand validity of the Overactive Bladder Symptom Score(OABSS) urodynamics[J]. Neurourol.Urodyn. 2003,22:105-108.